Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zhilong Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6946-8686; OpenAlex author ID A5085720070. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 2 papers

Papers 3

  1. The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC/YAP signaling pathway. Co-author DOI 10.1016/j.tranon.2025.102346↗
  2. TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality. Co-author DOI 10.1136/gutjnl-2024-332782↗
  3. Mesenchymal Stromal Cell-Based Targeted Therapy Pancreatic Cancer: Progress and Challenges. Co-author DOI 10.3390/ijms24043559↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Xu · 3 shared papers, 2023–2025 · strength 0.64
  2. Xianjun Yu · 3 shared papers, 2023–2025 · strength 0.64
  3. Si Shi · 2 shared papers, 2025 · strength 0.43
  4. Qingcai Meng · 1 shared paper, 2025 · strength 0.22
  5. Miaoyan Wei · 1 shared paper, 2025 · strength 0.22
  6. Mingwei Dong · 1 shared paper, 2025 · strength 0.22
  7. Xuhui Tong · 1 shared paper, 2025 · strength 0.21
  8. Yalan Lei · 1 shared paper, 2025 · strength 0.21
  9. Mingming Xiao · 1 shared paper, 2025 · strength 0.21
  10. Bo Zhang · 1 shared paper, 2023 · strength 0.20
  11. Jie Hua · 1 shared paper, 2023 · strength 0.20
  12. Wei Wang · 1 shared paper, 2023 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.